The landscape of drug policy in the United States is undergoing a seismic shift, and California's AB-1021 is at the epicenter. The bill, part of the 2023-2024 legislative session, challenges long-standing perceptions of several Schedule 1 drugs, including heroin, LSD, cannabis, methaqualone, peyote, and notably, psychedelics like MDMA and psilocybin.

In a surprising turn of events, California Governor Gavin Newsom vetoed a bill this past Saturday that aimed to decriminalize the possession and personal use of several hallucinogens, including the widely discussed psychedelic mushrooms.